Advanced

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Dreyling, Martin; Jurczak, Wojciech; Jerkeman, Mats LU ; Silva, Rodrigo Santucci; Rusconi, Chiara; Trneny, Marek; Offner, Fritz; Caballero, Dolores; Joao, Cristina and Witzens-Harig, Mathias, et al. (2016) In The Lancet 387(10020). p.770-778
Abstract
Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Lancet
volume
387
issue
10020
pages
770 - 778
publisher
Elsevier Limited
external identifiers
  • pmid:26673811
  • scopus:84959074796
  • wos:000370418000036
ISSN
1474-547X
DOI
10.1016/S0140-6736(15)00667-4
language
English
LU publication?
yes
id
510f4b65-b6b9-4a3c-b3ad-77ea36e877ed (old id 8504580)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26673811?dopt=Abstract
date added to LUP
2016-01-05 20:22:56
date last changed
2017-11-12 04:07:53
@article{510f4b65-b6b9-4a3c-b3ad-77ea36e877ed,
  abstract     = {Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or refractory mantle-cell lymphoma. We undertook a phase 3 study to assess the efficacy and safety of ibrutinib versus temsirolimus in relapsed or refractory mantle-cell lymphoma.},
  author       = {Dreyling, Martin and Jurczak, Wojciech and Jerkeman, Mats and Silva, Rodrigo Santucci and Rusconi, Chiara and Trneny, Marek and Offner, Fritz and Caballero, Dolores and Joao, Cristina and Witzens-Harig, Mathias and Hess, Georg and Bence-Bruckler, Isabelle and Cho, Seok-Goo and Bothos, John and Goldberg, Jenna D and Enny, Christopher and Traina, Shana and Balasubramanian, Sriram and Bandyopadhyay, Nibedita and Sun, Steven and Vermeulen, Jessica and Rizo, Aleksandra and Rule, Simon},
  issn         = {1474-547X},
  language     = {eng},
  number       = {10020},
  pages        = {770--778},
  publisher    = {Elsevier Limited},
  series       = {The Lancet},
  title        = {Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.},
  url          = {http://dx.doi.org/10.1016/S0140-6736(15)00667-4},
  volume       = {387},
  year         = {2016},
}